|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Eplerenone#Pharmacology]] |
| {{Eplerenone}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Description==
| |
| | |
| INSPRA contains eplerenone, a blocker of aldosterone binding at the mineralocorticoid receptor.
| |
| | |
| Eplerenone is chemically described as Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ-lactone, methyl ester, (7α,11α,17α)-. Its empirical formula is C24H30O6 and it has a molecular weight of 414.50. The structural formula of eplerenone is represented below:
| |
| | |
| {|
| |
| |[[File:Eplerenone09.jpg|thumb|800px]]
| |
| |}
| |
| | |
| Eplerenone is an odorless, white to off-white crystalline powder. It is very slightly soluble in water, with its solubility essentially pH-independent. The octanol/water partition coefficient of eplerenone is approximately 7.1 at pH 7.0. | |
| | |
| INSPRA for oral administration contains 25 mg or 50 mg of eplerenone and the following inactive ingredients: lactose, microcrystalline cellulose, croscarmellose sodium, hypromellose, sodium lauryl sulfate, talc, magnesium stearate, titanium dioxide, polyethylene glycol, polysorbate 80, and iron oxide yellow and iron oxide red.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = INSPRA (EPLERENONE) TABLET, FILM COATED [G.D. SEARLE LLC DIVISION OF PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a55a39ff-1bd5-428b-a64f-c44262e2f3ed | publisher = | date = | accessdate = 28 February 2014 }}</ref>
| |
| ==References==
| |
| {{Reflist}}
| |
| | |
| [[Category:Aldosterone antagonists]]
| |
| [[Category:Pfizer]]
| |
| [[Category:Lactones]]
| |
| [[Category:Epoxides]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |